Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
Publication Title
Rheumatology (Oxford, England)
Document Type
Article
Publication Date
7-5-2022
Keywords
washington; swedish
Abstract
OBJECTIVES: Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of psoriatic arthritis (PsA) on patients.
METHODS: Patients with active PsA were enrolled into BE ACTIVE, a 48-week randomised controlled trial (NCT02969525). After week 48, patients could enter a 104-week open-label extension (NCT03347110), receiving bimekizumab 160 mg every four weeks. PRO measures assessed included arthritis pain visual analogue scale (VAS), Psoriatic Arthritis Impact of Disease (PsAID)-9, 36-Item Short Form Survey (SF-36), and Health Assessment Questionnaire-Disability Index (HAQ-DI). Results were analysed as mean (standard error [SE]) changes from baseline (CfB) from week 0 to the end of the open-label extension (3 years) and as percentage of patients reaching patient-acceptable symptom state (PASS) for global impact (PsAID-9 total score ≤4) and normal function (HAQ-DI total score
RESULTS: In 206 patients (mean age 49.3 years, 51.0% male), completion rate was high; 161 (78.2%) patients completed week 152. Bimekizumab treatment was associated with long-term sustained improvements in pain (arthritis pain VAS CfB; week 48: -29.9 [1.9]; week 152: -32.0 [1.9]) and fatigue (PsAID-9 fatigue CfB; -2.4 [0.2]; -2.7 [0.2]). High percentages of patients achieved acceptable symptom state (PsAID-9 PASS: 75.2%; 65.0%) and normalised function (HAQ-DI
CONCLUSIONS: Bimekizumab treatment was associated with long-term sustained improvements in pain and fatigue, reducing overall impact of PsA on patients. Physical function and quality of life improved up to 3 years.
TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02969525, NCT03347110.
Clinical Institute
Orthopedics & Sports Medicine
Specialty/Research Institute
Orthopedics
Specialty/Research Institute
Rheumatology
